Aurinia Pharmaceuticals Inc. (AUPH) NASDAQ
$4.90 (0.13) (-2.58%)
Market Cap: $727.43M
As of 04/25/24 09:37 AM EDT. Market open.
Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ
$4.90
(0.13) (-2.58%)
Market Cap: $727.43M
As of 04/25/24 09:37 AM EDT. Market open.
Add to Portfolio
aurinia pharmaceuticals is a biotechnology company located in 5120-75 street, edmonton, ... read more
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Peter Greenleaf
Full Time Employees
337
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Peter Greenleaf
Full Time Employees
337
Address
1203-4464 Markham St, British Columbia, Victoria, V8Z 7X8.
PRICE CHART FOR AURINIA PHARMACEUTICALS INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$4.90
Previous Close
$5.03
Days Range
$5 - $5.16
52 week range
$4.71 - $12.43
Volume
159,493
Avg. Volume (30 days)
1,317,262
Market Cap
$727.43M
Dividend Yield
-
P/E
-
Shares Outstanding
144,617,762
Open
$4.90
Previous Close
$5.03
Days Range
$5 - $5.16
52 week range
$4.71 - $12.43
Volume
159,493
Avg. Volume (30 days)
1,317,262
Market Cap
$727.43M
Dividend Yield
-
P/E
-
Shares Outstanding
144,617,762
FINANCIAL STATEMENTS FOR AURINIA PHARMACEUTICALS INC
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR AURINIA PHARMACEUTICALS INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Greenleaf Peter | Chief Executive Officer | Mar 06, 2024 | Sale | $5.60 | 126,981 | 711,094 | 1,522,114 | Mar 07, 2024, 04:46 PM |
| Miller Joseph M | Chief Financial Officer | Mar 06, 2024 | Sale | $5.60 | 34,811 | 194,942 | 495,928 | Mar 07, 2024, 04:44 PM |
| Donley Matthew Maxwell | EVP, Ops & Strategy | Mar 06, 2024 | Sale | $5.51 | 40,665 | 224,064 | 584,072 | Mar 07, 2024, 04:43 PM |
| Habig Scott Michael | Chief Commercial Officer | Mar 06, 2024 | Sale | $5.60 | 17,777 | 99,551 | 474,587 | Mar 07, 2024, 04:42 PM |
| Robertson Stephen P. | EVP, General Counsel | Mar 06, 2024 | Sale | $5.60 | 57,745 | 323,372 | 443,824 | Mar 07, 2024, 04:41 PM |
| Knappertz Volker | EVP, Research and Development | Feb 27, 2024 | Sale | $6.10 | 4,930 | 30,073 | 319,128 | Feb 29, 2024, 04:11 PM |
| Knappertz Volker | EVP, Research and Development | Feb 20, 2024 | Sale | $5.48 | 25,146 | 137,800 | 324,058 | Feb 22, 2024, 04:35 PM |
| Habig Scott Michael | Chief Commercial Officer | Feb 20, 2024 | Sale | $5.48 | 15,867 | 86,951 | 492,364 | Feb 22, 2024, 04:33 PM |
| Robertson Stephen P. | EVP, General Counsel | Mar 02, 2023 | Sale | $8.78 | 19,644 | 172,474 | 303,122 | Feb 22, 2024, 04:19 PM |
| Miller Joseph M | Chief Financial Officer | Mar 02, 2023 | Sale | $8.78 | 11,398 | 100,074 | 331,112 | Feb 22, 2024, 04:17 PM |
| Jayne David R.W. | Director | May 23, 2023 | Sale | $11.26 | 8,733 | 98,334 | 49,310 | May 23, 2023, 05:19 PM |
| Hagan Joseph P | Director | May 19, 2023 | Sale | $10.58 | 272 | 2,878 | 11,961 | May 23, 2023, 05:18 PM |
| Billen Daniel | Director | May 23, 2023 | Sale | $11.26 | 4,650 | 52,359 | 33,393 | May 23, 2023, 05:17 PM |
| MacKay-Dunn R. Hector | Director | May 23, 2023 | Sale | $11.26 | 4,818 | 54,251 | 24,225 | May 23, 2023, 05:16 PM |
| Leversage Jill | Director | May 23, 2023 | Sale | $11.26 | 4,815 | 54,217 | 18,528 | May 23, 2023, 05:14 PM |
| MILNE GEORGE M JR | Director | Mar 02, 2023 | Buy | $8.91 | 20,000 | 178,284 | 70,000 | Mar 06, 2023, 04:29 PM |
| Miller Joseph M | Chief Financial Officer | Mar 02, 2023 | Sale | $8.94 | 11,296 | 100,986 | 331,214 | Mar 06, 2023, 04:29 PM |
| Robertson Stephen P. | EVP, General Counsel | Mar 02, 2023 | Sale | $8.94 | 19,402 | 173,454 | 303,364 | Mar 06, 2023, 04:29 PM |
| Greenleaf Peter | Chief Executive Officer | Mar 02, 2023 | Sale | $8.94 | 32,750 | 292,785 | 982,968 | Mar 06, 2023, 04:27 PM |
| Donley Matthew Maxwell | Ex VP, Internal Operations | Nov 21, 2022 | Buy | $4.66 | 10,000 | 46,600 | 27,927 | Nov 23, 2022, 04:04 PM |
| Habig Scott Michael | Chief Commercial Officer | Nov 09, 2022 | Buy | $5.01 | 5,000 | 25,075 | 5,000 | Nov 14, 2022, 04:31 PM |
| Martin Michael Robert | Chief Business Officer | Nov 07, 2022 | Buy | $5.16 | 30,000 | 154,800 | 89,512 | Nov 09, 2022, 04:05 PM |
| Jayne David R.W. | Director | May 18, 2022 | Option Exercise | $3.62 | 10,000 | 36,200 | 40,000 | Jul 11, 2022, 06:16 AM |
| MacKay-Dunn R. Hector | Director | Mar 09, 2022 | Buy | $11.00 | 5,000 | 54,985 | 11,000 | Mar 11, 2022, 04:05 PM |
| MILNE GEORGE M JR | Director | Mar 04, 2022 | Buy | $10.82 | 5,000 | 54,100 | 50,000 | Mar 08, 2022, 04:06 PM |
| Martin Michael Robert | Chief Business Officer | Mar 02, 2022 | Sale | $12.01 | 4,849 | 58,236 | 59,512 | Mar 04, 2022, 04:13 PM |
| Donley Matthew Maxwell | Ex VP, Intern'l Operations | Mar 02, 2022 | Sale | $12.01 | 3,052 | 36,655 | 16,224 | Mar 04, 2022, 04:12 PM |
| Miller Joseph M | Chief Financial Officer | Mar 02, 2022 | Sale | $12.01 | 3,060 | 36,751 | 6,610 | Mar 04, 2022, 04:12 PM |
| Colao Massimilano | Chief Commercial Officer | Mar 02, 2022 | Sale | $12.01 | 3,205 | 38,492 | 13,495 | Mar 04, 2022, 04:11 PM |
| Greenleaf Peter | Chief Executive Officer | Mar 02, 2022 | Sale | $12.01 | 9,068 | 108,907 | 32,967 | Mar 04, 2022, 04:11 PM |
| Solomons Neil | Chief Medical Officer | Mar 02, 2022 | Sale | $12.01 | 4,846 | 58,200 | 90,953 | Mar 04, 2022, 04:10 PM |
| Huizinga Robert Bindert | EVP of Research | Mar 02, 2022 | Sale | $12.01 | 4,849 | 58,236 | 69,379 | Mar 04, 2022, 04:10 PM |
| Leversage Jill | Director | Dec 13, 2021 | Buy | $20.04 | 1,600 | 32,064 | 5,300 | Dec 15, 2021, 04:09 PM |
| Martin Michael Robert | Chief Business Officer | Nov 11, 2021 | Option Exercise | $18.38 | 29,000 | 533,020 | 95,861 | Nov 12, 2021, 04:18 PM |
| Martin Michael Robert | Chief Business Officer | Nov 10, 2021 | Sale | $31.14 | 60,000 | 1,868,500 | 76,861 | Nov 12, 2021, 04:18 PM |
| Martin Michael Robert | Chief Business Officer | Nov 09, 2021 | Sale | $30.17 | 50,000 | 1,508,500 | 126,861 | Nov 12, 2021, 04:18 PM |
| Martin Michael Robert | Chief Business Officer | Nov 11, 2021 | Sale | $29.01 | 40,000 | 1,160,280 | 66,861 | Nov 12, 2021, 04:18 PM |
| Solomons Neil | Chief Medical Officer | Nov 10, 2021 | Option Exercise | $5.83 | 100,000 | 583,200 | 187,299 | Nov 12, 2021, 04:13 PM |
| Solomons Neil | Chief Medical Officer | Nov 11, 2021 | Option Exercise | $5.30 | 100,000 | 530,000 | 187,299 | Nov 12, 2021, 04:13 PM |
| Solomons Neil | Chief Medical Officer | Nov 09, 2021 | Sale | $30.17 | 50,000 | 1,508,500 | 87,299 | Nov 12, 2021, 04:13 PM |
| Solomons Neil | Chief Medical Officer | Nov 11, 2021 | Sale | $28.89 | 100,000 | 2,889,000 | 87,299 | Nov 12, 2021, 04:13 PM |
| Solomons Neil | Chief Medical Officer | Nov 10, 2021 | Sale | $31.11 | 100,000 | 3,110,800 | 97,299 | Nov 12, 2021, 04:13 PM |
| Solomons Neil | Chief Medical Officer | Nov 01, 2021 | Option Exercise | $5.30 | 45,000 | 238,500 | 182,299 | Nov 03, 2021, 04:24 PM |
| Solomons Neil | Chief Medical Officer | Nov 01, 2021 | Sale | $31.64 | 45,000 | 1,423,800 | 137,299 | Nov 03, 2021, 04:24 PM |
| Martin Michael Robert | Chief Business Officer | Nov 01, 2021 | Option Exercise | $3.20 | 45,000 | 144,000 | 221,861 | Nov 03, 2021, 04:20 PM |
| Martin Michael Robert | Chief Business Officer | Nov 01, 2021 | Sale | $31.64 | 45,000 | 1,423,800 | 176,861 | Nov 03, 2021, 04:20 PM |
| Huizinga Robert Bindert | EVP of Research | Oct 25, 2021 | Option Exercise | $3.20 | 95,000 | 304,000 | 195,728 | Oct 26, 2021, 04:33 PM |
| Huizinga Robert Bindert | EVP of Research | Oct 25, 2021 | Sale | $29.75 | 130,000 | 3,867,500 | 65,728 | Oct 26, 2021, 04:33 PM |
| Huizinga Robert Bindert | EVP of Research | Sep 21, 2021 | Option Exercise | $2.86 | 27,136 | 77,715 | 133,228 | Sep 22, 2021, 04:53 PM |
| Huizinga Robert Bindert | EVP of Research | Sep 21, 2021 | Sale | $23.99 | 32,500 | 779,533 | 106,092 | Sep 22, 2021, 04:53 PM |
| Martin Michael Robert | Chief Business Officer | Sep 20, 2021 | Option Exercise | $5.30 | 28,500 | 151,050 | 205,361 | Sep 22, 2021, 04:31 PM |
| Martin Michael Robert | Chief Business Officer | Sep 21, 2021 | Option Exercise | $7.40 | 87,500 | 647,750 | 264,361 | Sep 22, 2021, 04:31 PM |
| Martin Michael Robert | Chief Business Officer | Sep 21, 2021 | Sale | $24.02 | 87,500 | 2,101,750 | 176,861 | Sep 22, 2021, 04:31 PM |
| Martin Michael Robert | Chief Business Officer | Sep 20, 2021 | Sale | $21.65 | 28,500 | 616,975 | 192,861 | Sep 22, 2021, 04:31 PM |
| Martin Michael Robert | Chief Business Officer | Sep 14, 2021 | Option Exercise | $5.30 | 44,000 | 233,200 | 220,861 | Sep 16, 2021, 05:01 PM |
| Martin Michael Robert | Chief Business Officer | Sep 14, 2021 | Sale | $21.78 | 44,000 | 958,220 | 206,861 | Sep 16, 2021, 05:01 PM |
| Martin Michael Robert | Chief Business Officer | Sep 13, 2021 | Option Exercise | $5.30 | 25,000 | 132,500 | 201,861 | Sep 14, 2021, 06:16 PM |
| Martin Michael Robert | Chief Business Officer | Sep 14, 2021 | Option Exercise | $4.25 | 90,000 | 382,500 | 266,861 | Sep 14, 2021, 06:16 PM |
| Martin Michael Robert | Chief Business Officer | Sep 14, 2021 | Sale | $21.19 | 90,000 | 1,907,217 | 176,861 | Sep 14, 2021, 06:16 PM |
| Martin Michael Robert | Chief Business Officer | Sep 10, 2021 | Sale | $19.80 | 25,000 | 495,000 | 176,861 | Sep 14, 2021, 06:16 PM |
| Huizinga Robert Bindert | EVP of Research | Sep 14, 2021 | Sale | $21.75 | 22,500 | 489,375 | 106,092 | Sep 14, 2021, 05:12 PM |
| Huizinga Robert Bindert | EVP of Research | Sep 10, 2021 | Sale | $19.80 | 10,000 | 197,950 | 133,592 | Sep 14, 2021, 05:12 PM |
| Solomons Neil | Chief Medical Officer | Sep 13, 2021 | Option Exercise | $3.20 | 150,000 | 480,000 | 287,299 | Sep 14, 2021, 05:11 PM |
| Solomons Neil | Chief Medical Officer | Sep 10, 2021 | Sale | $19.84 | 150,000 | 2,976,000 | 137,299 | Sep 14, 2021, 05:11 PM |
| Martin Michael Robert | Chief Business Officer | Sep 07, 2021 | Sale | $18.10 | 7,500 | 135,750 | 176,861 | Sep 08, 2021, 04:04 PM |
| Huizinga Robert Bindert | EVP of Research | Sep 07, 2021 | Sale | $18.30 | 5,000 | 91,500 | 138,592 | Sep 08, 2021, 04:03 PM |
| Martin Michael Robert | Chief Business Officer | Aug 26, 2021 | Sale | $17.81 | 22,500 | 400,725 | 184,361 | Aug 27, 2021, 04:09 PM |
| Solomons Neil | Chief Medical Officer | Aug 25, 2021 | Sale | $15.85 | 5,000 | 79,250 | 137,299 | Aug 26, 2021, 04:15 PM |
| Solomons Neil | Chief Medical Officer | Aug 09, 2021 | Sale | $16.03 | 45,000 | 721,350 | 142,299 | Aug 10, 2021, 04:11 PM |
| Martin Michael Robert | Chief Business Officer | Aug 09, 2021 | Sale | $16.01 | 5,000 | 80,050 | 206,861 | Aug 10, 2021, 04:09 PM |
| Martin Michael Robert | Chief Business Officer | Jul 28, 2021 | Sale | $13.86 | 5,000 | 69,300 | 211,861 | Jul 29, 2021, 04:09 PM |
| Martin Michael Robert | Chief Business Officer | Jun 22, 2021 | Sale | $13.76 | 5,000 | 68,800 | 216,861 | Jun 23, 2021, 04:06 PM |
| Donley Matthew Maxwell | Ex VP, Intern'l Operations | May 11, 2021 | Buy | $10.07 | 9,900 | 99,739 | 9,900 | May 12, 2021, 04:34 PM |
| Greenleaf Peter | Chief Executive Officer | May 11, 2021 | Buy | $10.71 | 5,125 | 54,891 | 13,453 | May 12, 2021, 04:32 PM |
| Solomons Neil | Chief Medical Officer | Mar 12, 2021 | Option Exercise | $3.02 | 40,000 | 120,800 | 227,299 | Mar 15, 2021, 04:36 PM |
| Solomons Neil | Chief Medical Officer | Mar 12, 2021 | Sale | $13.49 | 40,000 | 539,600 | 187,299 | Mar 15, 2021, 04:36 PM |
| MILNE GEORGE M JR | Director | Mar 05, 2021 | Buy | $13.00 | 5,000 | 65,000 | 45,000 | Mar 09, 2021, 04:25 PM |
| Leversage Jill | Director | Jan 29, 2021 | Buy | $16.03 | 1,200 | 19,236 | 1,200 | Feb 02, 2021, 03:22 PM |
| Leversage Jill | Director | Jan 29, 2021 | Buy | $16.03 | 400 | 6,412 | 400 | Feb 02, 2021, 03:22 PM |
| Hayden Michael R | Director | Jan 29, 2021 | Option Exercise | $5.79 | 95,000 | 550,100 | 95,000 | Feb 02, 2021, 03:18 PM |
| Robertson Stephen P. | EVP, General Counsel | Jan 28, 2021 | Buy | $16.14 | 900 | 14,526 | 2,720 | Jan 29, 2021, 12:24 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Greenleaf Peter | Chief Executive Officer | 03/06/2024 | 711,094 |
| Miller Joseph M | Chief Financial Officer | 03/06/2024 | 194,942 |
| Donley Matthew Maxwell | EVP, Ops & Strategy | 03/06/2024 | 224,064 |
| Habig Scott Michael | Chief Commercial Officer | 03/06/2024 | 99,551 |
| Robertson Stephen P. | EVP, General Counsel | 03/06/2024 | 323,372 |
| Knappertz Volker | EVP, Research and Development | 02/27/2024 | 30,073 |
| Knappertz Volker | EVP, Research and Development | 02/20/2024 | 137,800 |
| Habig Scott Michael | Chief Commercial Officer | 02/20/2024 | 86,951 |
| Robertson Stephen P. | EVP, General Counsel | 03/02/2023 | 172,474 |
| Miller Joseph M | Chief Financial Officer | 03/02/2023 | 100,074 |
| Jayne David R.W. | Director | 05/23/2023 | 98,334 |
| Hagan Joseph P | Director | 05/19/2023 | 2,878 |
| Billen Daniel | Director | 05/23/2023 | 52,359 |
| MacKay-Dunn R. Hector | Director | 05/23/2023 | 54,251 |
| Leversage Jill | Director | 05/23/2023 | 54,217 |
| MILNE GEORGE M JR | Director | 03/02/2023 | 178,284 |
| Miller Joseph M | Chief Financial Officer | 03/02/2023 | 100,986 |
| Robertson Stephen P. | EVP, General Counsel | 03/02/2023 | 173,454 |
| Greenleaf Peter | Chief Executive Officer | 03/02/2023 | 292,785 |
| Donley Matthew Maxwell | Ex VP, Internal Operations | 11/21/2022 | 46,600 |
| Habig Scott Michael | Chief Commercial Officer | 11/09/2022 | 25,075 |
| Martin Michael Robert | Chief Business Officer | 11/07/2022 | 154,800 |
| Jayne David R.W. | Director | 05/18/2022 | 36,200 |
| MacKay-Dunn R. Hector | Director | 03/09/2022 | 54,985 |
| MILNE GEORGE M JR | Director | 03/04/2022 | 54,100 |
| Martin Michael Robert | Chief Business Officer | 03/02/2022 | 58,236 |
| Donley Matthew Maxwell | Ex VP, Intern'l Operations | 03/02/2022 | 36,655 |
| Miller Joseph M | Chief Financial Officer | 03/02/2022 | 36,751 |
| Colao Massimilano | Chief Commercial Officer | 03/02/2022 | 38,492 |
| Greenleaf Peter | Chief Executive Officer | 03/02/2022 | 108,907 |
| Solomons Neil | Chief Medical Officer | 03/02/2022 | 58,200 |
| Huizinga Robert Bindert | EVP of Research | 03/02/2022 | 58,236 |
| Leversage Jill | Director | 12/13/2021 | 32,064 |
| Martin Michael Robert | Chief Business Officer | 11/11/2021 | 533,020 |
| Martin Michael Robert | Chief Business Officer | 11/10/2021 | 1,868,500 |
| Martin Michael Robert | Chief Business Officer | 11/09/2021 | 1,508,500 |
| Martin Michael Robert | Chief Business Officer | 11/11/2021 | 1,160,280 |
| Solomons Neil | Chief Medical Officer | 11/10/2021 | 583,200 |
| Solomons Neil | Chief Medical Officer | 11/11/2021 | 530,000 |
| Solomons Neil | Chief Medical Officer | 11/09/2021 | 1,508,500 |
| Solomons Neil | Chief Medical Officer | 11/11/2021 | 2,889,000 |
| Solomons Neil | Chief Medical Officer | 11/10/2021 | 3,110,800 |
| Solomons Neil | Chief Medical Officer | 11/01/2021 | 238,500 |
| Solomons Neil | Chief Medical Officer | 11/01/2021 | 1,423,800 |
| Martin Michael Robert | Chief Business Officer | 11/01/2021 | 144,000 |
| Martin Michael Robert | Chief Business Officer | 11/01/2021 | 1,423,800 |
| Huizinga Robert Bindert | EVP of Research | 10/25/2021 | 304,000 |
| Huizinga Robert Bindert | EVP of Research | 10/25/2021 | 3,867,500 |
| Huizinga Robert Bindert | EVP of Research | 09/21/2021 | 77,715 |
| Huizinga Robert Bindert | EVP of Research | 09/21/2021 | 779,533 |
| Martin Michael Robert | Chief Business Officer | 09/20/2021 | 151,050 |
| Martin Michael Robert | Chief Business Officer | 09/21/2021 | 647,750 |
| Martin Michael Robert | Chief Business Officer | 09/21/2021 | 2,101,750 |
| Martin Michael Robert | Chief Business Officer | 09/20/2021 | 616,975 |
| Martin Michael Robert | Chief Business Officer | 09/14/2021 | 233,200 |
| Martin Michael Robert | Chief Business Officer | 09/14/2021 | 958,220 |
| Martin Michael Robert | Chief Business Officer | 09/13/2021 | 132,500 |
| Martin Michael Robert | Chief Business Officer | 09/14/2021 | 382,500 |
| Martin Michael Robert | Chief Business Officer | 09/14/2021 | 1,907,217 |
| Martin Michael Robert | Chief Business Officer | 09/10/2021 | 495,000 |
| Huizinga Robert Bindert | EVP of Research | 09/14/2021 | 489,375 |
| Huizinga Robert Bindert | EVP of Research | 09/10/2021 | 197,950 |
| Solomons Neil | Chief Medical Officer | 09/13/2021 | 480,000 |
| Solomons Neil | Chief Medical Officer | 09/10/2021 | 2,976,000 |
| Martin Michael Robert | Chief Business Officer | 09/07/2021 | 135,750 |
| Huizinga Robert Bindert | EVP of Research | 09/07/2021 | 91,500 |
| Martin Michael Robert | Chief Business Officer | 08/26/2021 | 400,725 |
| Solomons Neil | Chief Medical Officer | 08/25/2021 | 79,250 |
| Solomons Neil | Chief Medical Officer | 08/09/2021 | 721,350 |
| Martin Michael Robert | Chief Business Officer | 08/09/2021 | 80,050 |
| Martin Michael Robert | Chief Business Officer | 07/28/2021 | 69,300 |
| Martin Michael Robert | Chief Business Officer | 06/22/2021 | 68,800 |
| Donley Matthew Maxwell | Ex VP, Intern'l Operations | 05/11/2021 | 99,739 |
| Greenleaf Peter | Chief Executive Officer | 05/11/2021 | 54,891 |
| Solomons Neil | Chief Medical Officer | 03/12/2021 | 120,800 |
| Solomons Neil | Chief Medical Officer | 03/12/2021 | 539,600 |
| MILNE GEORGE M JR | Director | 03/05/2021 | 65,000 |
| Leversage Jill | Director | 01/29/2021 | 19,236 |
| Leversage Jill | Director | 01/29/2021 | 6,412 |
| Hayden Michael R | Director | 01/29/2021 | 550,100 |
| Robertson Stephen P. | EVP, General Counsel | 01/28/2021 | 14,526 |
Load More Insider Transactions
FUNDS WITH A POSITION IN AURINIA PHARMACEUTICALS INC
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| BLACKROCK INC. | 8,921,049 | 0.00204% | 6.05% | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 1,569,136 | 0.00148% | 5.47% | Other |
| BALYASNY ASSET MANAGEMENT L.P. | 887,014 | 0.01% | 237.49% | Event Driven |
| RENAISSANCE TECHNOLOGIES LLC | 135,000 | 0.00188% | -79.64% | Other |
| ALPS ADVISORS INC | 100,524 | 0.00711% | -5% | Other |
| D. E. SHAW & CO., INC. | 92,562 | 0.00073% | -74.08% | Other |
| AQR CAPITAL MANAGEMENT LLC | 21,435 | 0.00036% | 15.2% | Other |
CHANGE IN SHARES OUTSTANDING FOR AURINIA PHARMACEUTICALS INC
STOCK BUYBACKS FOR AURINIA PHARMACEUTICALS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
0.59%
1Q
06/30/2023
0.64%
2Q
03/31/2023
0.73%
3Q
12/31/2022
1.07%
4Q
09/30/2022
1.29%
5Q
06/30/2022
1.39%
6Q
03/31/2022
1.42%
7Q
12/31/2021
7.86%
8Q
09/30/2021
11.87%
9Q
06/30/2021
12.06%
10Q
03/31/2021
12.78%
11Q
12/31/2020
13.43%
12Q
09/30/2020
17.43%
13Q
06/30/2020
27.64%
14Q
03/31/2020
28.05%
15Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR AURINIA PHARMACEUTICALS INC
LOADING...